Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Locally Advanced or Borderline Resectable Pancreatic Cancer: An Exploratory Study

NCT05908747 Phase 2 ACTIVE_NOT_RECRUITING

This study is designed to explore the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as peri-operative treatment in locally advanced or borderline resectable pancreatic cancer.

Details

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	29
Start date	2023-05-31
Completion	2026-05

Conditions

• Pancreatic Cancer

Interventions

• surufatinib + gemcitabine + nab-paclitaxel

Primary outcomes

• Surgical complete resection rate (R0) — about 2 years
  This is a complete macroscopic resection of the gross tumor with negative surgical margins

Countries

China